Orion OYJ (OTCMKTS:ORINY) Shares Down 3.2% – Here’s What Happened

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) traded down 3.2% on Wednesday . The stock traded as low as $33.6250 and last traded at $33.6250. 258 shares traded hands during trading, an increase of 46% from the average session volume of 176 shares. The stock had previously closed at $34.73.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ORINY shares. Zacks Research cut Orion OYJ from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Nordea Equity Research upgraded Orion OYJ from a “hold” rating to a “buy” rating in a report on Monday, October 6th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Orion OYJ presently has an average rating of “Moderate Buy”.

Orion OYJ Price Performance

The stock has a market cap of $9.49 billion, a P/E ratio of 27.12 and a beta of 0.04. The business has a 50-day simple moving average of $37.28 and a 200 day simple moving average of $37.09. The company has a current ratio of 1.86, a quick ratio of 1.05 and a debt-to-equity ratio of 0.15.

Orion OYJ (OTCMKTS:ORINY) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.40 EPS for the quarter. Orion OYJ had a return on equity of 32.13% and a net margin of 19.33%.The company had revenue of $494.69 million for the quarter. On average, analysts forecast that Orion OYJ Unsponsored ADR will post 1.18 earnings per share for the current year.

Orion OYJ Announces Dividend

The company also recently declared a dividend, which was paid on Friday, November 7th. Stockholders of record on Friday, October 17th were given a $0.2418 dividend. The ex-dividend date was Thursday, October 16th. This represents a dividend yield of 127.0%. Orion OYJ’s payout ratio is 26.61%.

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.